MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
26.10
-1.02
-3.76%
Closed 19:50 08/10 EDT
OPEN
27.39
PREV CLOSE
27.12
HIGH
27.68
LOW
24.80
VOLUME
316.05K
TURNOVER
0
52 WEEK HIGH
45.50
52 WEEK LOW
4.971
MARKET CAP
109.63M
P/E (TTM)
-4.7295
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CUE last week (0803-0807)?
Weekly Report · 1d ago
Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress
NASDAQ · 08/04 06:22
Cue Biopharma Names James Ahlers CFO
Dow Jones · 08/03 13:03
*Cue Biopharma Says Ahlers Brings More Than 25 Years of Highly Diversified Fincl Leadership Experience Across Public, Private Biotechnology Cos >CUE
Dow Jones · 08/03 12:33
*Cue Biopharma: Ahlers Served for Nearly 2 Decades as CFO of Intarcia Therapeutics >CUE
Dow Jones · 08/03 12:33
*Cue Biopharma Appoints James Ahlers as Chief Fincl Officer >CUE
Dow Jones · 08/03 12:31
Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Dow Jones · 08/03 12:30
Weekly Report: what happened at CUE last week (0727-0731)?
Weekly Report · 08/03 09:54
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.